Valneva: Lyme’s Worst Nightmare
If you’re into under-the-radar biotechs with real products and FDA stamps, Valneva (VALN) deserves your full attention. It may look like a small-cap underdog, but it’s already taken down one virus—and it’s coming for another.
Valneva is a French company, but you can buy its shares on the NASDAQ.
So what do they do?
Valneva is a French vaccine company that plays hard. They’ve already delivered vaccines for Japanese Encephalitis and Cholera, but now they’ve locked onto two viral targets:
🦟 Chikungunya – Already FDA-approved
🦠 Lyme disease – Next in line, and it’s personal
First: Chikungunya? Handled.
In 2023, Valneva launched VLA1553, the world’s first FDA-approved Chikungunya vaccine.
> No drama, just Valneva vs. Chikungunya.
The world had no jab—Valneva said “grab.”
First in class, now leading the pack.
VLA1553? Already in the bag. 💼
Next Target: Lyme Disease
This time, Valneva is teaming up with Pfizer to take down Lyme disease, which is rapidly spreading across North America and Europe.
Their vaccine candidate, VLA15, is:
1. The most advanced Lyme vaccine in clinical development
2. Currently in Phase 3 trials
3. Co-developed and co-funded by Pfizer
4. Targeting a multi-billion-dollar market
If approved, it’ll be the first Lyme vaccine in over 20 years—and likely the only one on the market for a while.
Bottom line:
✅ One FDA-approved vaccine already (Chikungunya)
🚀 Another in late-stage trials with Pfizer (Lyme)
💼 Small market cap (~$400–500M)
🌍 Global reach + real demand + no direct competition
🧬 Actual science, not just hype
No financial advice — just my personal take. I threw down $6,000.
⚠️ CAUTION ⚠️
I’m just throwing out stock picks that feel right. No promises, No refunds. Don’t blame me if your wallet catches a fever hahahahahaha
0 Comments